A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).
The purpose of this study is to observe and preliminary explore the efficacy and safety of the combination of Camrelizumab and Apatinib regimen in treating advanced hepatocellular carcinoma (HCC) participants who have progressed following prior Immune Checkpoint Inhibitors (ICIs) treatment.
Hepatocellular Carcinoma|Immune Checkpoint Inhibitors
DRUG: Camrelizumab combined Apatinib regimen
Objective Response Rate (ORR), Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)., Up to approximately 12 months
Progression-free survival(PFS), Progression-free survival(PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)., Up to approximately 12 months|Time to objective response(TTR), Time to objective response(TTR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), Up to approximately 12 months|Duration of Response (DoR), Duration of Response (DoR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)., Up to approximately 12 months|Disease Control Rate (DCR), Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)., Up to approximately 12 months|6-month survival rate, 6-month survival rate, Up to approximately 12 months|9-month survival rate, 9-month survival rate, Up to approximately 12 months|12-month survival rate, 12-month survival rate, Up to approximately 12 months|Overall survival(OS), Up to approximately 24 months|Safety as measured by the rate of AEs, SAEs and laboratory abnormalities, Safety as measured by the rate of AEs, SAEs and laboratory abnormalities (e.g. Grade 3 or higher per CTCAE v4 ), From the first assignment of informed consent form up to 90 days after the last dose
The purpose of this study is to observe and preliminary explore the efficacy and safety of the combination of Camrelizumab and Apatinib regimen in treating advanced hepatocellular carcinoma (HCC) participants who have progressed following prior Immune Checkpoint Inhibitors (ICIs) treatment.